ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Cerecor Inc

Cerecor Inc (CERC)

2.93
0.00
( 0.00% )
Updated: 19:00:00

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.93
Bid
2.87
Ask
2.95
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
2.93
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
192,382,000
Dividend Yield
-
PE Ratio
-17.87
Earnings Per Share (EPS)
-0.16
Revenue
1.92M
Net Profit
-31.54M

About Cerecor Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-

CERC Latest News

Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

Name change underscores the Company’s transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates...

Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including...

Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and...

Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF...

Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-on...

ROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...

Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance

An initial tranche of $20 million drawn at the loan closingFunds ongoing clinical development of key investigational product candidatesFinancing provides flexibility and extends runway through...

Cerecor to Participate in Upcoming Investor Conferences

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and...

Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates

Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19...

FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization...

Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel disease and ARDS...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CERC - Frequently Asked Questions (FAQ)

What is the current Cerecor share price?
The current share price of Cerecor is $ 2.93
How many Cerecor shares are in issue?
Cerecor has 192,382,000 shares in issue
What is the market cap of Cerecor?
The market capitalisation of Cerecor is USD 563.68M
What is the 1 year trading range for Cerecor share price?
Cerecor has traded in the range of $ 0.00 to $ 0.00 during the past year
What is the PE ratio of Cerecor?
The price to earnings ratio of Cerecor is -17.87
What is the cash to sales ratio of Cerecor?
The cash to sales ratio of Cerecor is 293
What is the reporting currency for Cerecor?
Cerecor reports financial results in USD
What is the latest annual turnover for Cerecor?
The latest annual turnover of Cerecor is USD 1.92M
What is the latest annual profit for Cerecor?
The latest annual profit of Cerecor is USD -31.54M
What is the registered address of Cerecor?
The registered address for Cerecor is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Cerecor website address?
The website address for Cerecor is www.avalotx.com
Which industry sector does Cerecor operate in?
Cerecor operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NXUNXU Inc
$ 1.4516
(496.38%)
359.04M
WATTEnergous Corporation
$ 1.5806
(284.39%)
157.58M
INTZIntrusion Inc
$ 5.68
(162.96%)
107.97M
CYNCYNGN Inc
$ 1.299
(106.88%)
55.86M
HOLOMicroCloud Hologram Inc
$ 4.31
(79.58%)
84.35M
ABPAbpro Holdings Inc
$ 2.02
(-55.01%)
1.23M
TRAWTraws Pharma Inc
$ 7.75
(-42.25%)
834.64k
LITMSnow Lake Resources Ltd
$ 1.13
(-29.38%)
42.42M
LGHLWLion Group Holding Ltd
$ 0.0052
(-25.71%)
54.71k
BITSGlobal X Blockchain and Bitcoin Stratagy ETF
$ 66.5854
(-24.73%)
7.5k
NXUNXU Inc
$ 1.4591
(499.47%)
359.09M
VINCVincerx Inc
$ 0.3497
(80.26%)
286.42M
XTIAXTI Aerospace Inc
$ 0.03995
(1.14%)
163.36M
WATTEnergous Corporation
$ 1.5883
(286.26%)
157.58M
INTZIntrusion Inc
$ 5.675
(162.73%)
107.98M

CERC Discussion

View Posts
AliasUser1 AliasUser1 3 years ago
New board is: https://investorshub.advfn.com/Avalo-Therapeutics-AVTX-40053/
👍️0
frankkruemmel frankkruemmel 4 years ago
$cerc Cerecor wins Fast Track Designation https://www.biospace.com/article/2021-covid-19-news-india-variant-a-global-concern-low-risk-of-serious-long-term-effects-and-more/
👍️0
JohnLocke101 JohnLocke101 4 years ago
And up 25% this morning
👍️0
make it happen make it happen 4 years ago
Biggest negative operating margin ever seen -706.02%, book value $0.30 prob even less after earnings, some of the biggest negative returns see as well. Negative -$40+ million operating cash flow is real bad.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -706.02%

Management Effectiveness
Return on Assets (ttm) -74.02%
Return on Equity (ttm) -282.65%

Income Statement
Revenue (ttm) 6.7M
Revenue Per Share (ttm) 0.09
Gross Profit (ttm) -18.54M
EBITDA -45.45M
Net Income Avi to Common (ttm) -64.38M

Balance Sheet
Total Cash (mrq) 18.92M
Total Cash Per Share (mrq) 0.2
Total Debt (mrq) 1.46M
Total Debt/Equity (mrq) 5.96
Current Ratio (mrq) 1.71
Book Value Per Share (mrq) 0.30

Cash Flow Statement
Operating Cash Flow (ttm) -40.54M
Levered Free Cash Flow (ttm) -11.15M
👍️0
frankkruemmel frankkruemmel 4 years ago
https://www.marketwatch.com/story/cerecors-investigational-covid-19-therapy-gets-fast-track-designation-from-the-fda-2021-05-11
👍️0
JohnLocke101 JohnLocke101 4 years ago
Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
👍️0
JohnLocke101 JohnLocke101 4 years ago
“Oppenheimer Weighs in on Cerecor Inc.’s FY2025 Earnings (NASDAQ:CERC)”

Read Here
👍️0
JohnLocke101 JohnLocke101 4 years ago
Hanging strong in a volatile Daq market. Lots of news on their pipeline coming.

Good Luck!
👍️0
JohnLocke101 JohnLocke101 4 years ago
Nice move in the overall market rally. Needs to go up above that 50dma and make it support. We’re close.
👍️0
JohnLocke101 JohnLocke101 4 years ago
Just a heads up that CERC filed a $150 mil shelf registration yesterday. 2021 is a pivotal year for this company so I’m not surprised by it but it’s worth noting.

Good Luck!
👍️0
CYDYWinning CYDYWinning 4 years ago
Same
👍️0
JohnLocke101 JohnLocke101 4 years ago
Added at 3.04 on the dip.

Good Luck!
👍️0
JohnLocke101 JohnLocke101 4 years ago
Starter position on this dip under $3
👍️0
Billydakidd Billydakidd 4 years ago
Let’s gooooo
👍️0
Dubster watching Dubster watching 4 years ago
$2.60 in
👍️0
Stockyang Stockyang 4 years ago
Bought a lot of shares. Ready for a bull run soonish.
👍️0
swingingRichard swingingRichard 4 years ago
Interesting

👍️0
PennyWorld PennyWorld 4 years ago
COVID related update. Fundamentals are Excellent ... https://finance.yahoo.com/news/cerecor-announces-first-patient-enrolled-110010883.html
👍️0
PennyWorld PennyWorld 5 years ago
MASSIVE Insider Buying over past week !!


Transaction Date Insider Name Title Buy/Sell Number of Shares Average Share Price Total Transaction Shares Held After

Transaction Details
6/11/2020 Armistice Capital Master Fund Major Shareholder Buy 2,049,486 $2.44 $5,000,745.84

6/11/2020 Armistice Capital, Llc Director Buy 28,000 $2.44 $68,320.00

6/10/2020 Christopher Ryan Sullivan CFO Buy 2,954 $2.28 $6,735.12 2,954

6/9/2020 Armistice Capital, Llc Director Buy 1,753,680 $2.50 $4,384,200.00

6/9/2020 James Archie Harrell Jr Insider Buy 10,000 $2.50 $25,000.00 21,618

6/9/2020 Michael F Cola CEO Buy 100,000 $2.50 $250,000.00 175,746
👍️0
Jcbaby1 Jcbaby1 5 years ago
News out today read here: Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
DOWNLOAD AS PDFMAY 26, 2020
- Patients hospitalized with COVID-19 had significantly elevated levels of the inflammatory cytokine LIGHT

- LIGHT was strongly linked with mortality (82%) in patients over 60 years of age

- Decreasing LIGHT levels using CERC-002 (anti-LIGHT mAb) may prevent cytokine storm induced severe ARDS and thereby reduce mortality and the need for ventilation

ROCKVILLE, Md., May 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC) and Myriad Genetics Inc. (NASDAQ: MYGN) today announced that levels of novel cytokine, LIGHT, were highly correlated with disease severity and mortality in a COVID-19 acute respiratory distress syndrome (ARDS) biomarker study. The biomarker study was conducted using the serum samples of 47 hospitalized COVID-19 patients and 30 healthy controls from Hackensack Meridian Health Network.

In April 2020, approximately 1,500 people in the United States died each day from COVID-19. The viral infection triggers a hyperactive immune response leading to cytokine storm and Acute Respiratory Distress Syndrome (ARDS), which is a leading cause of death in patients who die of COVID-19. Although this hyperinflammatory process is poorly understood, the data from this study implicates the inflammatory cytokine, LIGHT, as a potential key driver of cytokine storm leading to ARDS and death.

LIGHT levels were significantly elevated in the serum of hospitalized patients with COVID-19 versus healthy controls (p value < 0.0001). The highest LIGHT levels were found in patients who required ventilator support, particularly in patients over 60. Importantly, the data demonstrated elevated LIGHT levels were also strongly linked with mortality (p=0.02).

Dr. David Perlin, Ph.D., chief scientific officer, senior vice president of the Center for Discovery and Innovation, and Professor of Medical Sciences at the Hackensack Meridian School of Medicine at Seton Hall University, commented “These data are compelling and demonstrate that the inflammatory cytokine LIGHT may play a key role in cytokine storm associated with COVID-19 ARDS that leads to increased morbidity and mortality. Reducing LIGHT levels might be a key to dampening the cytokine storm in these patients, preventing the need for ventilator support and reducing mortality.”

Dr. Garry Neil, M.D. chief scientific officer, Cerecor commented, “As a company, we recognized the impact of cytokine storm-induced ARDS and the need for treatment options for patients in this area of high unmet need. We remain focused on the CERC-002 clinical program and rapidly moving it forward for the treatment of cytokine storm induced ARDS.”

Role of LIGHT in Acute Inflammatory Response

LIGHT (homologous to Lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes) is a cytokine with inflammatory actions encoded by the TNFSF14 gene. LIGHT has been shown to play a key role in the immune response to viral pneumonia. LIGHT plays an important role in regulating immune responses in the lung, gut and skin. It stimulates T Cell and B Cell response as well as induces the release of other cytokines such as IL1, IL6, IL-8, IL-10, TNF and GM-CSF.

CERC-002 (anti-LIGHT monoclonal antibody)

CERC-002 is a fully human monoclonal antibody with neutralizing action against LIGHT (TNFSF14), for treatment of children with Pediatric Crohn’s Disease. Cerecor holds an open IND with FDA and the drug is currently being studied in a Phase I clinical trial for patients with refractory severe Crohn’s disease, currently not recruiting due to COVID-19
👍️0
Chrisny73 Chrisny73 5 years ago
looks like they acquired product lines and not the company itself
👍️0
TheFinalCD TheFinalCD 5 years ago
according to the SEC doc. AYTU acquired CERC

https://www.sec.gov/Archives/edgar/data/1385818/000165495419013534/aytu_425.htm


Message in reply to:

Gnmx aquired by Cerc
👍️0
tonyjh tonyjh 5 years ago
Yeah. I used to have this under a dollar. Bought back in yesterday. Accumulation line looks real proper.
👍️0
Chrisny73 Chrisny73 5 years ago
Looks like this stock took a beating after the acquisition if GNMX which I wasa shareholder of...
👍️0
StocktonCA StocktonCA 5 years ago
Gnmx aquired by Cerc!! on our way up!!! glta :)
👍️0
sanderburwil sanderburwil 5 years ago
$7-$8 coming
👍️0
jcbaby jcbaby 5 years ago
This company is going to be exciting soon will be keeping watch on this one
👍️0
whytestocks whytestocks 5 years ago
News: $CERC Cerecor Reports Second Quarter 2019 Results

-Positive Final Results with CERC-301 in nOH -First Patient Enrolled in CDG FIRST Trial - FDA Acceptance of IND Application of CERC-802 ROCKVILLE, Md., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development an...

Read the whole news Cerecor Reports Second Quarter 2019 Results
👍️0
whytestocks whytestocks 6 years ago
News: $CERC Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH)

ROCKVILLE, Md., July 01, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive results from its comp...

Find out more https://marketwirenews.com/news-releases/cerecor-announces-positive-final-results-of-cerc-301-in-the-tre-8438912.html
👍️0
whytestocks whytestocks 6 years ago
News: $CERC Cerecor Added to Russell 3000® Index

ROCKVILLE, Md., June 28, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it has been added to the ...

Read the whole news https://marketwirenews.com/news-releases/cerecor-added-to-russell-3000-xae-index-8429182.html
👍️0
whytestocks whytestocks 6 years ago
News: $CERC Cerecor Set to Join Russell 3000® Index

ROCKVILLE, Md., June 11, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it is set to join the Rus...

In case you are interested https://marketwirenews.com/news-releases/cerecor-set-to-join-russell-3000-xae-index-8339290.html
👍️0
FreedFish FreedFish 6 years ago
Anybody out there following this growing company? Management moves awesome. Follow Boyd/Armistice and the path to success!!! Freed.
👍️0
JBowsNose JBowsNose 7 years ago
Beast
👍️0
stocktrademan stocktrademan 7 years ago
CERC buy 4.93

hammer candlestick at moving average support
bullish engulfing pattern
uptrending great and about to breakout over major resistance
chart really shows how the inverted head and shoulders bottom causes an uptrend that can last months and years
ascending triangle breakout with pullback
at a support level for a low risk high reward trade



https://www.cerecor.com/



















normal chart




log chart



👍️0
europtiger europtiger 7 years ago
CERC about to Break 52 week high
👍️0
pietro13 pietro13 7 years ago
Bullish triangle breakout on 15-Feb-2018
👍️0
cash_cow1 cash_cow1 7 years ago
Whatever is happening to this market, I'm glad it is not affecting Cerecor inc. The stock is holding up very well in this rough market. The DOW and NASDAQ took a beating yesterday. I thought Friday was bad, but it was nothing like yesterday, when the DOW was down nearly 1200 point. That was nerve wrecking.
👍️0
crudeoil24 crudeoil24 7 years ago
Hedge funds loading.
👍️0
europtiger europtiger 7 years ago
Weeee
👍️0
europtiger europtiger 7 years ago
Running nice
👍️0
axelvento axelvento 7 years ago
$2.7 . bouncer . CERC
👍️0
cash_cow1 cash_cow1 7 years ago
Happy New Year to all of Cerecor Inc shareholders and investors.
👍️0
cash_cow1 cash_cow1 7 years ago
Back from the Christmas Holidays. Back in at $2.70, let's get going CERC.
👍️0
europtiger europtiger 7 years ago
Market maker magic from 4,10 to 3,80's with like noch Volume lol
👍️0
europtiger europtiger 7 years ago
Wooowzaaaaa
👍️0
europtiger europtiger 7 years ago
New 52 week high
👍️0
europtiger europtiger 7 years ago
Go CERC
👍️0
axelvento axelvento 7 years ago
true monster $$$$$$ . CERC
👍️0
Expresso123 Expresso123 7 years ago
axelvento grazie che hai postato mesi fa su CERC, tu hai promosso il tuo diritto grazie! Tutto il meglio per te 2018
👍️0
Expresso123 Expresso123 7 years ago
2018 going be huge not worth flipping
👍️0